Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
2014-January Volume 7 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
2014-January Volume 7 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect

  • Authors:
    • Feng Kong
    • Yun Luan
    • Zhao‑Hua Zhang
    • Guang‑Hui Cheng
    • Tong‑Gang Qi
    • Chao Sun
  • View Affiliations / Copyright

    Affiliations: Central Research Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China, Department of Pediatrics, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China
  • Pages: 254-259
    |
    Published online on: October 29, 2013
       https://doi.org/10.3892/etm.2013.1369
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The aim of the present study was to investigate the protective effect of baicalin (BA) against ischemia‑reperfusion (I/R) injury in isolated rat hearts. Sprague‑Dawley rat hearts were rapidly removed, mounted on a Langendorff apparatus and subjected to 30 min ischemia followed by 30 min reperfusion with Krebs‑Henseleit (K‑H) solution at 37˚C to establish the isolated I/R injury model. All animals (n=50) were randomly divided into five groups (n=10 in each): I, normal control; II, I/R; III, I/R plus 20 mg/kg BA; IV, I/R plus 40 mg/kg BA; and V, I/R plus 80 mg/kg BA. The degree of heart injury caused by the I/R was assessed by evaluating left ventricular function and by detecting the levels of lactate dehydrogenase (LDH) and creatine kinase (CK) in the coronary effluent and the myocardial superoxide dismutase (SOD) and malondialdehyde (MDA) levels in the isolated rat hearts. Myocardial infarct size and vascular density were assessed using histology and immunohistochemistry. The apoptotic cardiomyocytes were determined using flow cytometry (FCM). Compared with group II, the BA groups demonstrated improved left ventricular function, reduced CK and LDH release in the coronary effluent and increased SOD and MDA activity (P<0.05). Furthermore, histology and immunohistochemistry results showed that the infarct size was reduced and vessel density was augmented in the BA groups (P<0.01) compared with group II. The FCM results indicated that apoptosis was significantly lower in the BA groups than in group II (P<0.05) and that the protective effect was dose‑dependent. In conclusion, these results demonstrated that BA exerts a dose‑dependent protective effect on I/R injury in isolated rat hearts, the mechanisms of which may be associated with antioxidant and anti‑apoptosis properties. To the best of our knowledge, this study is the first evaluation of the efficacy of BA in isolated rat hearts using histology and immunohistochemistry, providing a foundation for the use of BA in the treatment of acute myocardial infarction.

Introduction

Ischemia-reperfusion (I/R) injury remains the leading cause of morbidity and mortality in all developed countries and is a large economic burden in the treatment and care of patients (1). I/R injury of the heart is the underlying pathophysiology of acute myocardial infarction (AMI), which is one of the most common causes of mortality globally (2). Following cell I/R, apoptosis is one of the major pathways that leads to the process of cell death. Numerous studies have indicated that cell apoptosis is associated with a variety of damaging stimuli, particularly continuous I/R, in vitro and in the intact heart in vivo(3–7). Thus, protection against I/R injury in the heart is of marked importance.

Chinese herbal medicine has been used to treat diseases for thousands of years and it has recently attracted the attention of practitioners of Western medicine. However, the effective ingredients in the majority of these medications have not been identified. Baicalin (BA; C21H18O11, 7-glucuronic acid, 5,6-dihydroxy-flacone), a Chinese traditional medicinal herb, possesses antioxidant properties and free radical scavenging activity (8–12). Studies have demonstrated that BA can suppress the proliferation of vascular smooth muscle cells (9) and exert cardioprotective effects against hypoxia/reoxygenation injury (12–16). However, the cardioprotective properties have not been confirmed and the mechanism has not been fully characterized. In addition, there has been no clear histological or immunohistochemical evidence showing the cardioprotective effect of BA to date. Therefore, further studies investigating the mechanisms of protection are required.

The Langendorff mouse heart model is widely used in studies of myocardial function and responses to injury (17). In the present study, rat hearts were isolated and perfused using the Langendorff technique to establish a high-throughput and potentially reliable I/R model.

The aim of the present study was to evaluate the efficacy of BA in isolated rat hearts using hemodynamic, histological and immunohistochemical observations.

Materials and methods

Animals

Male Sprague-Dawley rats, weighing 250–300 g, were purchased from the Experimental Animal Center of Shandong University (Jinan, China). The rats were housed within the animal care facility at a constant room temperature with a 12:12-h light-dark cycle and were provided with standard rat chow and water ad libitum for at least 3 days prior to the initiation of the experiments. All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH publication no. 85-23; revised 1996). The study was approved by the Ethics Committee of the Shandong University (Jinan, China).

Langendorff isolated perfused heart preparation

Rats were anesthetized with pentobarbital sodium (50 mg/kg ip) and administered with the anticoagulant, heparin sodium (10,000 USP U/kg ip). Following this, a thoracotomy was performed and the hearts of the rats were rapidly excised into ice-cold arresting solution (120 mmol/l NaCl and 30 mmol/l KCl). The aorta was cannulated on a 20-gauge stainless steel blunt needle and perfusion was initiated at 70 mmHg on a Langendorff apparatus. A modified Krebs-Henseleit (K-H) perfusion solution was used in all experiments, containing 118 mmol/l NaCl, 4.7 mmol/l KCl, 2.5 mmol/l CaCl2, 1.2 mmol/l MgSO4, 1.2 mmol/l KH2PO4, 24 mmol/l NaHCO3, 5.5 mmol/l glucose, 5.0 mmol/l sodium pyruvate and 0.5 mmol/l EDTA bubbled with 95% O2-5% CO2 at 37°C (pH 7.4). Electrodes were placed in the upper left and lower right regions of the heart and a left ventricular catheter with a pressure transducer (TP-400T; Nihon Kohden Corp., Tokyo, Japan) was connected to the Medlab Biosignal Acquisition System (MedLab-U/4C501, Top Instrument Co., Ltd., Hangzhou, China), to record heart rate (HR), left ventricular end-diastolic pressure (LVEDP), left ventricular developed pressure (LVDP), mean coronary flow (CF) and the first derivative of the left ventricular pressure during a cardiac cycle (maximum and minimum LV dP/dt). Heart pacing at 360 beats/min was initiated following 30 min stabilization to normalize HR across the groups. All hemodynamic parameters were continuously recorded on an eight-channel thermal-pen recorder (WT-685G; Nihon Kohden Corp.). Coronary effluent samples were obtained at 5, 15, 25, 35, 45 and 55 min of perfusion, and stored at −20°C for the measurement of lactate dehydrogenase (LDH) and creatine kinase (CK) activity. At the end of reperfusion, the left ventricular free wall was rapidly excised and stored at −80°C for subsequent determination of the levels of antioxidant enzymes.

Experimental protocols

BA (purity >95%) was purchased from Sigma (St. Louis, MO, USA) and dissolved in saline prior to being added into the perfusion solution. All hearts were perfused with the K-H solution for a total of 120 min (at 37°C), consisting of a 30-min preischemic period followed by 30 min of ischemia and 60 min of reperfusion. The hearts were randomly divided into five experimental groups. Group I (normal): Hearts (n=10) were perfused for 90 min with K-H solution as a normal control for the different experimental groups. Group II (I/R): Following equilibration, hearts (n=10) were subjected to ischemia for 30 min, prior to being reperfused for 60 min with K-H solution. Groups III, IV and V (I/R plus BA): Hearts (n=10 each) were perfused similarly to group II, except that the reperfusion solution contained 20, 40 and 80 mg/kg BA, respectively.

Assessment of myocardial damage

Activities of CK and LDH in the coronary effluent were measured by a 722 Visible Spectrophotometer (Shanghai Laipade Science Instruments Co., Ltd, Shanghai, China) using a Sigma assay kit at 340 nm, as described previously (18). Samples of the perfusate and the coronary effluent were collected following 5, 15, 25, 35 and 60 min of reperfusion and frozen in liquid nitrogen.

The malondialdehyde (MDA) level and superoxide dismutase (SOD) activity in the frozen myocardial tissue were measured using commercial kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) with the 722 Visible Spectrophotometer at 532 nm (19). The cardiac tissue samples were weighed and homogenized (1:10, w/v) in 50 mmol/l phosphate buffer and maintained in an ice bath. The amount of thiobarbituric acid-reactive substances was estimated as MDA and SOD equivalents per gram of wet myocardial weight.

Evaluation of myocardial infarct size

Following reperfusion and the rapid excision of the heart, the tissues were fixed with 10% formaldehyde, cut transversely, from apex to base, into six slices and embedded in paraffin. Serial sections (1 cm) of the embedded tissue were stained with hematoxylin-eosin and Masson’s trichrome stain (Baso Biotechnology, Shenzhen, China) and the amount of surviving myocardium was measured using Masson’s stain. For each slice, the area at risk and the area of infarction were determined by the sum of the planimetered endocardial and epicardial circumferences of the infarcted area divided by the sum of the total endocardial and epicardial circumferences of the left ventricle, as described previously (20,21).

Analysis of vessel density

The hearts were rapidly harvested and the tissues in the infarcted zone were collected. The tissues were subsequently embedded in optimal cutting temperature compound (Sigma), rapidly frozen in liquid nitrogen and stored at −80°C. Having been fixed in acetone for 10 min at 4°C, cryostat sections were then cut into 5-μm slices and incubated with primary antibodies. Immunohistochemical staining was performed with an antibody against von Willebrand factor (vWF; 1:100; Abcam, Cambridge, UK), in accordance with the manufacturer’s instructions. The vascular density was counted blind on 100 sections in the infarcted areas of all animals and then stained with an anti-vWF antibody, using a light microscope at a magnification of ×400. The average of the 10 high-power fields (hpfs) was randomly selected and the vascular density was defined as the number of vessels/hpf in the infarcted area (0.2 mm2). Samples were randomized and two examiners, blind to treatment design, were used for analysis.

Assay of apoptosis

Cardiomyocyte apoptosis was analyzed via flow cytometry (FCM) using a FACSCalibur system with CellQuest acquisition software (BD Pharmingen, Inc., San Diego, CA, USA) (22). Briefly, a single-cell suspension the from minced tissue of the LV free wall was obtained by mechanical grinding, prior to filtration through 40-μm nylon mesh filters (Falcon Cell Strainers; BD Biosciences Discovery Labware, Bedford, MA, USA). FCM analysis was performed using an Annexin V-fluorescein isothiocyanate (FITC) kit (Immunotech, Beckman Coulter, Miami, FL, USA) according to the manufacturer’s instructions: 500 μl 1X Binding Buffer was mixed with 10 μl propidium iodide (PI) and 10 μl Annexin-V labeled with FITC solutions. The cells were washed twice with ice-cold phosphate-buffered saline and then incubated for 15 min in 100 μl fresh incubation buffer containing PI and FITC-Annexin-V in the dark at room temperature. Following this, the cells (>1×106/ml) were analyzed as soon as possible (within 1 h) using FCM.

Statistical analysis

All data are presented as the mean ± standard error of the mean. A Student’s t-test was used to compare the data between two groups and one-way analysis of variance was used to compare the data from more than two groups, followed by the Scheffe multiple-comparison test. Statistical analyses were performed using SPSS version 13.0 statistical software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of BA on hemodynamics and LV function

There were no significant differences in the baseline values of the cardiovascular parameters, including LVEDP, LVDP, CF and maximum and minimum LV dp/dt, between any of the groups. BA infusion caused virtually no changes in any of the measured cardiovascular parameters prior to ischemia in the ischemic groups. During the 30 min ischemia, LVDP, CF and maximum and minimum LV dp/dt decreased in all the groups. At 60 mins of reperfusion, these parameters showed partial recoveries in the I/R groups. Recoveries of LVDP, CF and maximum and minimum LV dp/dt were significantly improved in groups III, IV and IV compared with those in group II, in a dose-dependent manner (P<0.05). LVEDP was significantly increased during the 30 min of ischemia, and increased again at the end of the 60-min K-H solution reperfusion period (P<0.05). However, the increases in LVEDP during reperfusion in groups III, IV and V were significantly smaller than those in group II, as previously reported (23).

Effect of BA on LDH and CK in coronary effluent

In all the groups, the activities of LDH and CK in the coronary effluent prior to ischemia were minimal. However, following ischemia, in group II, releases of LDH and CK into the coronary effluent were significantly increased compared with the normal group and significantly decreased in groups III, IV and V compared with group II (Table I).

Table I

Effect of baicalin on LDH and CK activity in the coronary effluent.

Table I

Effect of baicalin on LDH and CK activity in the coronary effluent.

Reperfusion, U/ml

GroupParameterPreischemia5 min15 min25 min35 min45 min55 min
IICK33±2.658±3.760±4.562±1.763±6.365±4.568±5.8
LDH2.38±0.210.27±0.310.26±0.19.48±0.29.25±0.59.16±0.18.70±0.4
IIICK32±3.757±5.155±4.9a49±8.1a42±3.4a38±2.6b36±1.4b
LDH2.43±0.69.61±0.78.13±0.4a7.25±0.8a6.38±0.9b5.10±0.4b4.90±0.6b
IVCK34±2.856±3.855±2.6a47±6.3a39±1.8bc37±4.7bc35±2.1bc
LDH2.36±1.79.37±1.37.37±1.3a6.28±1.2a5.34±1.2bc4.60±0.8bc3.60±0.7bc
VCK32±4.256±2.652±2.4a45±1.7a36±4.9ac34±4.7bcd33±4.5bd
LDH2.36±1.79.24±1.37.26±2.0a5.80±3.2a4.80±1.3bcd4.20±0.8bd3.40±1.7bd

{ label (or @symbol) needed for fn[@id='tfn1-etm-07-01-0254'] } Data are presented as the mean ± standard error of the mean (n=10).

a P<0.05 and

b P<0.01, vs. group II;

c P<0.05, vs. group III;

d P<0.05, vs. group IV.

{ label (or @symbol) needed for fn[@id='tfn6-etm-07-01-0254'] } LDH, lactate dehydrogenase; CK, creatine kinase.

Effect of BA on SOD and MDA in myocardial tissue

The level of myocardial MDA was significantly higher and SOD was significantly lower in the ischemia groups than those in the normal group (P<0.01). However, the levels were significantly improved in groups III, IV and V than those in group II, with the results showing a dose-dependent effect (Table II).

Table II

Effect of baicalin on SOD activity and MDA content in I/R-induced myocardial tissue.

Table II

Effect of baicalin on SOD activity and MDA content in I/R-induced myocardial tissue.

ParameterControlGroup IIGroup IIIGroup IVGroup V
SOD (U/g)441.3±14.3180.6±23.7a246.7±19.5b345.4±13.4a,b,c408.0±18.6a,b,c,d
MDA (mmol/g)61.2±5.8270.7±3.8a206.2±7.6a,b148.4±5.1a,b,c80.7±4.1a,b,c,d

{ label (or @symbol) needed for fn[@id='tfn7-etm-07-01-0254'] } Data are presented as the mean ± standard error of the mean (n=10).

a P<0.05, vs. control;

b P<0.05, vs. group II;

c P<0.05, vs. group III;

d P<0.05, vs. group IV.

{ label (or @symbol) needed for fn[@id='tfn12-etm-07-01-0254'] } SOD, superoxide dismutase; MDA, malondialdehyde; I/R, ischemia-reperfusion.

Infarct size and vessel density analysis

The infarct size was significantly increased in group II (65.3±4.2%) compared with the control group (10.6±3.5; P<0.001). Furthermore, the infarct size was significantly decreased in groups III (43.8±2.7), IV (38.7±2.3) and V (35.4±3.1) compared with group II (P<0.05, Fig. 1). The vessel density was significantly reduced in group II (5.3±1.05) compared with the control group (12.7±1.08; P<0.001), while it was significantly increased in groups III (8.2±1.36), IV (9.6±1.24) and V (10.4±1.09) compared with group II (P<0.05, Fig. 2)

Figure 1

Effects of BA on myocardial infarct size visualized with Masson’s trichrome. Compared with the (A) control group, the infarct size was significantly increased in (B) group II. By contrast, it was significantly decreased in groups (C) III, (D) IV and (E) V compared with group II (magnification, ×100). Group I (control): Hearts were perfused for 90 min with K-H solution as a normal control for the different experimental groups. Group II (I/R): Subsequent to equilibration, hearts were subjected to ischemia for 30 min followed by reperfusion for 60 min with K-H solution. Groups III, IV and V (I/R + BA): Hearts were perfused similarly to group II, except that the reperfusion solution contained 20, 40 and 80 mg/kg BA, respectively. BA, baicalin; K-H, Krebs-Henseleit; I/R, ischemia-reperfusion.

Figure 2

Effects of BA on vessel density. Vessels were stained with von Willebrand factor. Compared with the (A) control group, the density of the vessels was significantly reduced in (B) group II. By contrast, the density was significantly increased in groups (C) III, (D) IV and (E) V compared with group II (magnification, ×100). Group II (I/R): Subsequent to equilibration, hearts were subjected to ischemia for 30 min followed by reperfusion for 60 min with K-H solution. Groups III, IV and V (I/R + BA): Hearts were perfused similarly to group II, except that the reperfusion solution contained 20, 40 and 80 mg/kg BA, respectively. BA, baicalin; K-H, Krebs-Henseleit; I/R, ischemia-reperfusion.

Apoptosis detected by FCM

Following cell labeling with Annexin-V-FITC and PI, FCM analysis of the cardiomyocytes revealed that the percentage of apoptotic cells following I/R was significantly increased compared with normal cells (20.33 vs. 23%). Following BA treatment (20, 40 or 80 mg/kg), the percentage of apoptotic cardiomyocytes was significantly increased (P<0.05) in a dose-dependent manner (18.32, 14.95 and 10.12%, respectively).

Discussion

Scutellaria baicalensis Georgi is a widely used herb in traditional medical systems of China and Japan (24). Flavonoids, including baicalein, BA, wogonin and skullcap flavones I and II, are major components of Scutellaria baicalensis Georgi and have been suggested to exert antioxidant and other pharmacological effects. The variety of interesting effects exhibited by BA has led to it attracting considerable attention and it has been widely used in oriental medicine. Studies have previously demonstrated the protective effects exerted by BA in myocardial ischemia in the isolated rat heart and against hypoxia/reoxygenation damage in rat cardiomyocytes (12–16). The mechanisms behind this protection may be due to the antioxidant, prooxidant and anti-inflammatory effects of BA, induced by the hypoxia/reoxygenation injury to cardiomyocytes. However, the mechanisms are still not fully understood and, therefore, further studies into the mechanisms of protection are required.

I/R injury remains the leading cause of morbidity and mortality in all developed countries and is a large economic burden on the treatment and care of patients. Following cell I/R, apoptosis is one of the major pathways leading to cell death (25,26). Programmed cell death, in the form of apoptosis, necrosis and, possibly, autophagic cell death are the final arbiters of cardiomyocyte numbers following myocardial infarction (27–29). Apoptosis has been ascribed a pathogenic role in I/R, particularly in the heart and brain (30,31). It has been indicated that cell apoptosis is associated with a variety of damaging stimuli, particularly continuous I/R. Therefore, the inhibition of cardiomyocyte apoptosis induced by myocardial I/R injury in the heart is particularly important for reducing myocardial damage.

In the present study, an isolated Langendorff-perfused rat heart model was used to evaluate the protective effect of BA against I/R injury. The heart was exposed to ischemia for 30 min and then reperfused with K-H perfusion solution for 60 min to establish an I/R model in vitro. It has previously been shown that BA is able to reduce LDH leakage and increase the survival rate of cardiomyocytes undergoing I/R (7). In our experiment, the activities of LDH and CK in the coronary effluent in the I/R group were significantly increased compared with those in the normal group. Furthermore, LDH and CK activities were significantly decreased in the BA groups, compared with group II, in a dose-dependent manner (P<0.05). By contrast, the myocardial MDA and SOD levels in the BA groups were significantly lower than those in group II (P<0.05). Our results indicated that the protective effects of BA against I/R injury were mediated by its antioxidant activity.

As mentioned previously, studies have demonstrated that BA is able to suppress the proliferation of vascular smooth muscle cells and exert cardioprotective effects against hypoxia/reoxygenation injury. However, the mechanisms are complicated, and, to date, there has been no clear histological and immunohistochemical evidence showing the cardioprotective effects of BA. To further study the protective effect of BA, the efficacy of BA was evaluated in isolated rat hearts using histology and immunohistochemistry and cardiomyocyte apoptosis was measured using FCM. The results showed that infarct size was reduced and vessel density was augmented in the BA groups (P<0.01). Labeling the cardiomyocytes with Annexin-V-FITC and PI showed that the percentage of apoptotic cells in I/R injury was significantly increased compared with normal cells (P<0.05). Following BA treatment (20, 40 and 80 mg/kg), the percentage of apoptotic cardiomyocytes was significantly increased (P<0.05) in a dose-dependent manner.

In conclusion, our data suggest a dose-dependent protective effect of BA against I/R injury in isolated rat hearts and indicate that the mechanisms of the protective effect may be associated with antioxidant and anti-apoptotic properties. To the best of our knowledge, this study is the first evaluation of the efficacy of BA in isolated rat hearts using histology and immunohistochemistry and may provide a theoretical foundation for the clinical treatment of AMI. Further studies in this field are must be performed.

Acknowledgements

The authors thank The Second Hospital of Shandong University and the Beijing University of Aeronautics and Astronautics for their generous support.

References

1 

Garg HK and Bryan NS: Dietary sources of nitrite as a modulator of ischemia/reperfusion injury. Kidney Int. 75:1140–1144. 2009.PubMed/NCBI

2 

Xiao CY, Yuhki K, Hara A, et al: Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation. 109:2462–2468. 2004. View Article : Google Scholar : PubMed/NCBI

3 

Zhang WH, Fu SB, Lu FH, et al: Involvement of calcium-sensing receptor in ischemia/reperfusion-induced apoptosis in rat cardiomyocytes. Biochem Biophys Res Commun. 347:872–881. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Wang YL, Wang CY, Zhang BJ and Zhang ZZ: Shenfu injection suppresses apoptosis by regulation of Bcl-2 and caspase-3 during hypoxia/reoxygenation in neonatal rat cardiomyocytes in vitro. Mol Biol Rep. 36:365–370. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Eefting F, Rensing B, Wigman J, Pannekoek WJ, Liu WM, Cramer MJ, Lips DJ and Doevendans PA: Role of apoptosis in reperfusion injury. Cardiovasc Res. 61:414–426. 2004. View Article : Google Scholar : PubMed/NCBI

6 

Dumont EA, Hofstra L, van Heerde WL, et al: Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation. 102:1564–1568. 2000. View Article : Google Scholar : PubMed/NCBI

7 

Borutaite V, Jekabsone A, Morkuniene R and Brown GC: Inhibition of mitochondrial permeability transition prevents mitochondrial dysfunction, cytochrome c release and apoptosis induced by heart ischemia. J Mol Cell Cardiol. 35:357–366. 2003. View Article : Google Scholar

8 

Gao Z, Huang K, Yang X and Xu H: Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta. 1472:643–650. 1999. View Article : Google Scholar : PubMed/NCBI

9 

Dethlefsen SM, Sherpo D and D’Amore P: Arachindonic acid metabolites in bFGF-, PDGF-, and serum-stimulated vascular cell growth. Exp Cell Res. 212:262–273. 1994. View Article : Google Scholar : PubMed/NCBI

10 

Li BQ, Fu T, Dongyan Y, Mikovits JA, Ruscetti FW and Wang JM: Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry. Biochem Biophys Res Commun. 276:534–538. 2000. View Article : Google Scholar : PubMed/NCBI

11 

Chou TC, Chang LP, Li CY, Wong CS and Yang SP: The antiinflammatory and analgesic effects of baicalin in carrageenan-evoked thermal hyperalgesia. Anesth Analg. 97:1724–1729. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Lin CC and Shieh DE: The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med. 24:31–36. 1996.

13 

Kubo M, Matsuda H, Tanaka M, Kimura Y, Okuda H, Higashino M, Tani T, Namba K and Arichi S: Studies on Scutellariae radix. VII. Anti-arthritic and anti-inflammatory actions of methanolic extract and flavonoid components from Scutellariae radix. Chem Pharm Bull (Tokyo). 32:2724–2729. 1984. View Article : Google Scholar : PubMed/NCBI

14 

Xiping Z, Hua T, Hanqing C, Li C, Zhiwei W, Keyi W, Wei Y, Yun L, Qingyu L, Qing H and Fei W: The protecting effects and mechanisms of Baicalin and Octreotide on heart injury in rats with SAP. Mediators Inflamm. 2007:194692007. View Article : Google Scholar : PubMed/NCBI

15 

Woo AY, Cheng CH and Waye MM: Baicalein protects rat cardiomyocytes from hypoxia/reoxygenation damage via a prooxidant mechanism. Cardiovasc Res. 65:244–253. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Lin L, Wu XD, Davey AK and Wang J: The anti-inflammatory effect of baicalin on hypoxia/reoxygenation and TNF-alpha induced injury in cultural rat cardiomyocytes. Phytother Res. 24:429–437. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Reichelt ME, Willems L, Hack BA, Peart JN and Headrick JP: Cardiac and coronary function in the Langendorff-perfused mouse heart model. Exp Physiol. 94:54–70. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Yamashiro S, Kuniyoshi Y, Arakaki K, Uezu T, Miyagi K and Koja K: Cardioprotective effects of tetrahydrobiopterin in cold heart preservation after cardiac arrest. Ann Thorac Cardiovasc Surg. 12:95–104. 2006.PubMed/NCBI

19 

Yamashiro S, Noguchi K, Matsuzaki T, Miyagi K, Nakasone J and Sakanashi M, Koja K and Sakanashi M: Beneficial effect of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. J Thorac Cardiovasc Surg. 124:775–784. 2002. View Article : Google Scholar : PubMed/NCBI

20 

Luan Y, Liu XC, Zhang GW, Shi RF, Zhao XB, Zhao CH, Liu TJ, Lü F, Yang Q and He GW: Mid-term effect of stem cells combined with transmyocardial degradable stent on swine model of acute myocardial infarction. Coron Artery Dis. 21:233–243. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Wang Y, Liu XC, Zhang GW, et al: A new transmyocardial degradable stent combined with growth factor, heparin, and stem cells in acute myocardial infarction. Cardiovasc Res. 84:461–469. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Slama P, Sladek Z, Rysanek D and Langrova T: Effect of Staphylococcus aureus and Streptococcus uberis on apoptosis of bovine mammary gland lymphocytes. Res Vet Sci. 87:233–238. 2009.

23 

Ouyang HC, Wu JL and Chen JH: Protective effect of baicalin aganist myocardial ischemia and reperfusion injury in rats. Chin J New Drugs Clin Rem. 256:408–412. 2006.(In Chinese).

24 

Shao ZH, Vanden Hoek TL, Qin Y, Becker LB, Schumacker PT, Li CQ, Dey L, Barth E, Halpern H, Rosen GM and Yuan CS: Baicalein attenuates oxidant stress in cardiomyocytes. Am J Physiol Heart Circ Physiol. 282:H999–H1006. 2002.PubMed/NCBI

25 

Zhang Z, Yu B and Tao GZ: Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin Med J (Engl). 122:2360–2365. 2009.PubMed/NCBI

26 

Mani K: Programmed cell death in cardiac myocytes: strategies to maximize post-ischemic salvage. Heart Fail Rev. 13:193–209. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Kang PM and Izumo S: Apoptosis in heart: basic mechanism and implications in cardiovascular diseases. Trends Mol Med. 9:177–182. 2003. View Article : Google Scholar : PubMed/NCBI

28 

Saraste A, Voipio-Pulkki LM, Parvinen M and Pulkki K: Apoptosis in the heart. N Engl J Med. 336:1025–1026. 1997. View Article : Google Scholar : PubMed/NCBI

29 

Kim NH and Kang PM: Kang: Apoptosis in cardiovascular diseases: mechanism and clinical implications. Korean Circ J. 40:299–305. 2010. View Article : Google Scholar : PubMed/NCBI

30 

Umansky SR, Shapiro JP, Cuenco GM, Foehr MW, Bathurst IC and Tomei LD: Prevention of rat neonatal cardiomyocyte apoptosis induced by simulated in vitro ischemia and reperfusion. Cell Death Differ. 4:608–616. 1997. View Article : Google Scholar : PubMed/NCBI

31 

Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, De Muinck E, Wellens HJ, Kemerink GJ, Reutelingsperger CP and Heidendal GA: Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 356:209–212. 2000. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Kong F, Luan Y, Zhang ZH, Cheng GH, Qi TG and Sun C: Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect. Exp Ther Med 7: 254-259, 2014.
APA
Kong, F., Luan, Y., Zhang, Z., Cheng, G., Qi, T., & Sun, C. (2014). Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect. Experimental and Therapeutic Medicine, 7, 254-259. https://doi.org/10.3892/etm.2013.1369
MLA
Kong, F., Luan, Y., Zhang, Z., Cheng, G., Qi, T., Sun, C."Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect". Experimental and Therapeutic Medicine 7.1 (2014): 254-259.
Chicago
Kong, F., Luan, Y., Zhang, Z., Cheng, G., Qi, T., Sun, C."Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect". Experimental and Therapeutic Medicine 7, no. 1 (2014): 254-259. https://doi.org/10.3892/etm.2013.1369
Copy and paste a formatted citation
x
Spandidos Publications style
Kong F, Luan Y, Zhang ZH, Cheng GH, Qi TG and Sun C: Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect. Exp Ther Med 7: 254-259, 2014.
APA
Kong, F., Luan, Y., Zhang, Z., Cheng, G., Qi, T., & Sun, C. (2014). Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect. Experimental and Therapeutic Medicine, 7, 254-259. https://doi.org/10.3892/etm.2013.1369
MLA
Kong, F., Luan, Y., Zhang, Z., Cheng, G., Qi, T., Sun, C."Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect". Experimental and Therapeutic Medicine 7.1 (2014): 254-259.
Chicago
Kong, F., Luan, Y., Zhang, Z., Cheng, G., Qi, T., Sun, C."Baicalin protects the myocardium from reperfusion‑induced damage in isolated rat hearts via the antioxidant and paracrine effect". Experimental and Therapeutic Medicine 7, no. 1 (2014): 254-259. https://doi.org/10.3892/etm.2013.1369
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team